Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.  |
AIDS TREATMENT NEWS - June 12, 2004
John S. James
Summary: GlaxoSmithKline is offering research grants to scientists for certain innovative projects involving the development of HIV treatment, vaccines, or microbicides.
GlaxoSmithKline will award a total of $250,000 for innovative HIV/AIDS treatment, vaccine, or microbicide drug discovery and development research (from $25,000 to $150,000 for each grant). Researchers must submit applications by July 31, 2004 and the grants will be paid on December 1. There is no obligation to license resulting technology to the company.
In the previous three years of the program, GSK has awarded $1.25 million to 14 researchers.
For more information about the GSK Drug Discovery and Development Research Grant Program, and for an application, call 1-888-527-6935 or visit http://www.dddresearchgrant.com
040612
ATN040605
Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .